The CpG island methylator phenotype (CIMP) in colorectal cancer

Gastroenterology and Hepatology from Bed to Bench

Volumn 6, Issue 3, 2013, Pages 120-128

  Mojarad, Ehsan Nazemalhosseini ^a   Kuppen, Peter J K ^b   Aghdaei, Hamid Asadzadeh ^a   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CIMP; Clinical implication; Colorectal Cancer

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; K RAS PROTEIN;

BRAF GENE; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CDKN2A GENE; CLINICAL FEATURE; COLON CANCER; COLORECTAL CANCER; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MOLECULAR GENETICS; ONCOGENE K RAS; PATHOPHYSIOLOGY; PROMOTER REGION; REVIEW; TREATMENT RESPONSE;

EID: 84880002767     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int 2012;1-11.
2. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-97.
3. Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007 ;120:656-63.
4. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010 ;138:2029-43.
5. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010; 31:31-38.
6. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073-87.
7. Wu C, Bekaii-Saab T. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract 2012; 2012:359041.
8. Samowitz WS, Curtin K, Wolff RK, Tripp SR, Caan BJ, Slattery ML. Microsatellite instability and survival in rectal cancer. Cancer Causes Control 2009; 20:1763-68.
9. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol 2011; 5:385-99.
10. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010; 138:2059-72.
11. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23:11-27.
12. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004; 432:338-41.
13. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J. Mutations in APC, Kirsten-ras and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99:9433-38.
14. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3:433-8.
15. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002; 89:845-60.
16. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Nati Acad Sci U S A 1999; 96: 8681-8686.
17. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8:686-700.
18. Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012; 1825:77-85.
19. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.
20. Kaneda A, Yagi K. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci 2011; 102:18-24.
21. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999; 9:349-57.
22. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004; 14:427-32.
23. de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruïne AP, et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG islandhypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009 ;18:3086-96.
24. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002; 51:797-802.
25. Ahuja N, Issa JP. Aging, methylation and cancer. Histol Histopathol 2000; 15:835-842.
26. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5:2220-22.
27. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41:1350-53.
28. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009 ;41:178-86.
29. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-93.
30. Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010; 10:227.
31. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007; 104:18654-59.
32. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38:787-93.
33. Ahuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, Baylin SB, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57:3370-74.
34. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122: 1376-87.
35. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003; 21: 3729-36.
36. Shen L, Catalano PJ, Benson AB, 3rd, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13:6093-98.
37. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68:8541-46.
38. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylatorphenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8:582-88.
39. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55:1000-1006.
40. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007; 450:529-37.
41. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9:305- 14.
42. Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 2008; 132:1657-65.
43. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, et al. Three DNA Methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010; 16:21-33.
44. Deng G, Kakar S, Tanaka H, Matsuzaki K, Miura S, Sleisenger MH, et al. Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer 2008; 44:1290-301.
45. Miller S, Steele S. Novel molecular screening approaches in colorectal cancer. J Surg Oncol 2012; 105:459-67.
46. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer 2011; 128:1080-94.
47. Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, et al. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 1999; 57:149-56.
48. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58:104-13.
49. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-94.
50. Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 2009; 96: 1196-204.
51. Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, et al. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. Arch Pathol Lab Med 2008; 132: 958-64.
52. Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 2006; 66: 8462-68.
53. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005; 129: 837-45.
54. Ferracin M, Gafà R, Miotto E, Veronese A, Pultrone C, Sabbioni S, et al. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. J Pathol 2008; 214: 594- 602.
55. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62: 2370- 77.
56. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 1731-38.
57. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 3573-77.
58. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res 2011; 185: 99-115.
59. Laru AV, Cheng Y, Agarwal R, Yang J, David S, Abraham JM, et al. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm Bowel Dis 2012; 18: 641-48.
60. Sanchez JA, Dejulius KL, Bronner M, Church JM, Kalady MF. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Inflamm Bowel Dis 2011; 17: 1966-70.
61. Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer 2010; 9: 167-72.
62. Khamas A, Ishikawa T, Mogushi K, Iida S, Ishiguro M, Tanaka H, et al. Genome-wide screening for methylation-silenced genes in colorectal cancer. Int J Oncol 2012; 41: 490-96.
63. Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011; 140: 1174-81.
64. Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011; 117: 1847-54.
65. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5- fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-903.
66. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96.